CEPI Funds Moderna, Oxford/SII, IAVI for Bundibugyo Ebola Vaccine Development

CEPI Funds Moderna, Oxford/SII, IAVI for Bundibugyo Ebola Vaccine Development | Quick Digest
The Coalition for Epidemic Preparedness Innovations (CEPI) has committed approximately $60 million to Moderna, the University of Oxford (with Serum Institute of India), and the International AIDS Vaccine Initiative (IAVI) to accelerate the development of vaccines against the Bundibugyo ebolavirus, currently causing an outbreak in the Democratic Republic of Congo and Uganda. This urgent funding aims to fast-track investigational vaccines towards clinical trials.

Key Highlights

  • CEPI provides approximately $60 million for Bundibugyo Ebola vaccine development.
  • Moderna, Oxford/SII, and IAVI are key recipients of the funding.
  • Moderna secures up to $50 million for its mRNA vaccine candidate.
  • Oxford University and Serum Institute of India receive $8.6 million.
  • IAVI granted $3.2 million for its rVSV-based vaccine candidate.
  • Funding addresses an ongoing Ebola Bundibugyo outbreak in DRC and Uganda.
The Coalition for Epidemic Preparedness Innovations (CEPI) has announced a significant investment of approximately $60 million to rapidly advance the development of three investigational vaccine candidates targeting the Bundibugyo ebolavirus. This deadly strain is currently responsible for a rapidly spreading outbreak in the Democratic Republic of Congo (DRC) and neighboring Uganda, which has been declared a public health emergency by global health agencies. The funding initiative, reported by Reuters and widely corroborated by multiple news outlets on June 1-2, 2026, aims to fast-track these vaccine candidates towards clinical trials, a critical step given the absence of any licensed vaccines or treatments specifically for the Bundibugyo strain. Moderna, a prominent biotechnology company known for its mRNA vaccine technology, will receive the largest share, up to $50 million. This substantial investment is earmarked for the preclinical development and Phase 1 clinical testing of Moderna's mRNA-based Bundibugyo ebolavirus vaccine candidate. The funding will also support parallel manufacturing activities to ensure that doses can be produced simultaneously with clinical evaluation, enabling a rapid transition to large-scale Phase 2/3 trials if early safety and immunogenicity data are positive. Another significant recipient is the University of Oxford, in collaboration with the Serum Institute of India (SII). They will receive up to $8.6 million from CEPI. This funding is designated for preclinical testing and other development activities required to quickly prepare for Phase 1 trials of a vaccine based on Oxford's ChAdOx1 platform, the same technology that underpinned the widely used Oxford/AstraZeneca COVID-19 vaccine. The Serum Institute of India, a key global vaccine manufacturer, will be responsible for manufacturing clinical-grade doses and creating a Master Virus Seed stock under a pre-existing agreement with CEPI, highlighting India's crucial role in global vaccine accessibility and development. The third recipient of CEPI's emergency funding is the International AIDS Vaccine Initiative (IAVI), which will receive an initial commitment of $3.2 million. This funding will support the preparations necessary to generate a Master Virus Seed stock and initiate testing of its recombinant vesicular stomatitis virus (rVSV)-based vaccine candidate. This platform is notable as it forms the basis of an approved and WHO-prequalified vaccine against the more common Zaire strain of Ebola. Experts from the World Health Organization (WHO) have identified IAVI's single-dose rVSV candidate as highly promising for the Bundibugyo virus. CEPI's strategy involves supporting a portfolio of candidates utilizing different vaccine technologies to maximize the chances of success in rapidly developing an effective countermeasure. Richard Hatchett, CEO of CEPI, emphasized the urgency, stating that 'every day counts in the race against this deadly disease' given the rapid spread of the Bundibugyo virus. He expressed hope that trials could begin within a couple of months, acknowledging the unpredictable nature of vaccine development and the complex security situation in eastern Congo that could pose challenges to trials. The current outbreak has resulted in hundreds of confirmed cases and dozens of deaths in the DRC and Uganda, with estimates suggesting over 1,000 suspected cases and more than 250 deaths, although accurate tallies are difficult to ascertain due to various factors. The declaration of a Public Health Emergency of International Concern (PHEIC) by the WHO and a Public Health Emergency of Continental Security (PHECS) by the Africa CDC underscores the gravity of the situation. This funding from CEPI is part of broader global efforts to combat the Ebola outbreak. Other organizations, such as the global vaccine alliance Gavi, have committed up to $50 million to the Ebola response, and the World Bank's Pandemic Fund announced grants totaling up to $220.6 million. The involvement of the Serum Institute of India is particularly relevant for an Indian audience, as it highlights India's critical role in global health initiatives and vaccine manufacturing capacity. This collaboration leverages SII's proven capability, demonstrated during the COVID-19 pandemic, to produce vaccines at scale, which is essential for ensuring equitable access in affected regions.

Frequently Asked Questions

What is the Bundibugyo ebolavirus and why is urgent vaccine development needed?

The Bundibugyo ebolavirus is a strain of Ebola currently causing a rapidly spreading outbreak in the Democratic Republic of Congo and Uganda. Urgent vaccine development is critical because there are currently no licensed vaccines or specific treatments available for this particular strain, and the outbreak has been declared a public health emergency.

Which organizations are receiving funding for Ebola vaccine development and what are their contributions?

The Coalition for Epidemic Preparedness Innovations (CEPI) is providing approximately $60 million to three groups: Moderna (up to $50 million for its mRNA vaccine), the University of Oxford (with Serum Institute of India for $8.6 million for its ChAdOx1-based vaccine), and the International AIDS Vaccine Initiative (IAVI) ($3.2 million for its rVSV-based vaccine). Each brings a different proven vaccine technology to the effort.

What role does the Serum Institute of India play in this global effort?

The Serum Institute of India (SII) is playing a crucial role by manufacturing clinical-grade doses of the Oxford University's Bundibugyo ebolavirus vaccine candidate. This partnership leverages SII's extensive manufacturing capabilities, essential for producing vaccines at scale and ensuring global access.

When can we expect these investigational vaccines to be ready for trials?

CEPI CEO Richard Hatchett indicated that it might be possible to get the Bundibugyo Ebola vaccines ready for clinical trials within a couple of months. While vaccine development is unpredictable, the aim is to rapidly advance these candidates to human testing. The Oxford vaccine could be ready for trials in around six weeks.

What is CEPI's overall goal in funding these vaccine candidates?

CEPI's mission is to accelerate the development of vaccines against epidemic and pandemic threats. By funding multiple candidates with diverse technologies, CEPI aims to maximize the chances of developing safe and effective vaccines against the Bundibugyo ebolavirus as quickly as possible, complementing ongoing public health interventions. This aligns with CEPI's broader '100 Days Mission' to develop vaccines for new threats within 100 days.

Read Full Story on Quick Digest